Severity and prevalence of COVID-19 infection among patients with respiratory symptoms and history of four doses of vaccination
Severity and prevalence of COVID-19 infection among patients with respiratory symptoms and history of four doses of vaccination
Arash Letafati,1,*Elnaz Khodadoust Soufiani,2Zahra Heidary,3Kimia Mohajeri,4Ayeh Khorshidian,5Siavash Chalabiani,6
1. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 2. Department of Medical Laboratory Science, Faculty of Para Medicine, Islamic Azad University, Tehran Medical Branch, Tehran, Iran 3. Department of Virology, School of Public Health, Ahvaz University of Medical Sciences, Ahvaz, Iran 4. Department of Microbiology, School of Basic Sciences, Islamic Azad University, Tehran, Iran 5. Department of Biology, Faculty of Basic Sciences, Gonbad Kavous University, Gonbad Kavous, Iran 6. Department of Microbiology, School of Biological Science, Islamic Azad University, Qom Branch, Qom, Iran
Introduction: Acute respiratory infection (ARI) is a severe infection that affects a person's respiratory system and causes breathing problems. Coronaviridae is one of the viral families that cause respiratory infections in birds and mammals. The efficiency of vaccination against COVID-19 infection is undeniable so this study aimed to evaluate the symptoms of SARS-CoV-2 in people who received four doses of the Sinopharm vaccine
Methods: This study evaluated the prevalence and severity of COVID-19 infection in vaccinated people with four doses of sinopharm vaccine. All samples were collected from patients with respiratory symptoms who were referred to Besat hospital, Tehran, Iran
Results: From 290 patients with respiratory symptoms, 109 patients were positive for COVID-19 infection with a history of four doses of Sinopharm vaccine and the most common clinical symptom of infection were cough, runny nose, and fever but the hospitalization rate was very low.
Conclusion: Although vaccination can’t prevent infection with SARS-CoV-2, but against COVID-19 infection seems to be beneficial in reducing symptoms and hospitalization rate, especially if they have received a forth booster dose.